A M Mauer
Overview
Explore the profile of A M Mauer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
160
Citations
1230
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mauer A, Kraut E, Krauss S, Ansari R, Kasza K, Szeto L, et al.
Ann Oncol
. 2005 May;
16(8):1320-5.
PMID: 15919687
Background: The aim of the study was to evaluate the efficacy and tolerability of the combination of oxaliplatin, fluorouracil and leucovorin in patients with advanced esophagus cancer. Patients And Methods:...
2.
Winegarden J, Mauer A, Otterson G, Rudin C, Villalona-Calero M, Lanzotti V, et al.
Ann Oncol
. 2004 May;
15(6):915-20.
PMID: 15151948
Purpose: To evaluate the efficacy and toxicity of oxaliplatin and paclitaxel as first-line therapy for patients with advanced non-small-cell lung cancer (NSCLC). Patients And Methods: The treatment regimen was given...
3.
Vokes E, Gordon G, Mauer A, Rudin C, Krauss S, Szeto L, et al.
Clin Lung Cancer
. 2004 Jan;
2(2):128-32.
PMID: 14731323
STEALTH cisplatin (SPI-77) is a liposomal formulation of cisplatin that has activity in animal models of non small-cell lung cancer (NSCLC). Vinorelbine has documented clinical activity in NSCLC. The purpose...
4.
Mauer A, Ansari R, Hoffman P, Krauss S, Taber D, Tembe S, et al.
Ann Oncol
. 2003 Apr;
14(5):722-8.
PMID: 12702526
Background: The aim of this study was to evaluate feasibility and tolerability of the three-drug combination of paclitaxel, ifosfamide and carboplatin (TIC) in patients with advanced non-small-cell lung cancer. The...
5.
Villano J, Mauer A, Vokes E
Ann Oncol
. 2003 Mar;
14(4):656-8.
PMID: 12649117
No abstract available.
6.
Rudin C, Otterson G, Mauer A, Villalona-Calero M, Tomek R, Prange B, et al.
Ann Oncol
. 2002 Jun;
13(4):539-45.
PMID: 12056703
Background: Chemorefractory small-cell lung cancer (SCLC) is defined as disease that progresses during primary therapy or within 3 months of completion of primary therapy. Patients with chemorefractory SCLC have a...
7.
Eng C, Mauer A, Fleming G, Bertucci D, Rotmensch J, Jacobs R, et al.
Ann Oncol
. 2002 Feb;
12(12):1743-7.
PMID: 11843253
Background: The combination of doxorubicin, paclitaxel, and cisplatin has activity in gynecologic malignancies but requires colony stimulating factor (G-CSF) support. Moreover, there is concern about cardiotoxicity with doxorubicin/paclitaxel combinations. Pegylated...
8.
Vokes E, Gordon G, Rudin C, Mauer A, Watson S, Krauss S, et al.
Invest New Drugs
. 2001 Sep;
19(4):329-33.
PMID: 11561694
In a previous phase II trial of the synthetic topoisomerase I inhibitor, 9-aminocamptothecin (9-AC), given as a 72-h infusion, we identified modest single agent activity of 9% in patients with...
9.
George C, Haraf D, Mauer A, Krauss S, Hoffman P, Rudin C, et al.
Invest New Drugs
. 2001 Sep;
19(4):303-10.
PMID: 11561689
JM216 is an orally administered platinum analogue. We undertook this study to determine the maximally tolerated dose (MTD) of JM216 when administered with concomitant radiotherapy to the chest (200 cGy...
10.